Walter Klemp V - 16 Jun 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan P. Foster by Power of Attorney
Issuer symbol
MBRX
Transactions as of
16 Jun 2025
Net transactions value
-$278
Form type
4
Filing time
18 Jun 2025, 21:00:17 UTC
Previous filing
06 Nov 2024
Next filing
23 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KLEMP WALTER V CEO and President, Director C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON /s/ Jonathan P. Foster by Power of Attorney 18 Jun 2025 0000938419

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +1,667 +2.9% 58,702 16 Jun 2025 Direct F1
transaction MBRX Common Stock Tax liability $278 -406 -0.69% $0.6852 58,296 16 Jun 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -1,667 -0.45% $0.000000 370,075 16 Jun 2025 Common Stock 1,667 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards
F3 On June 16, 2021, the reporting person was granted 6,668 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.